Sophiris Bio to Present at the Jefferies 2014 Global Healthcare Conference

Jefferies 2014 Global Healthcare Conference

SAN DIEGO & VANCOUVER, British Columbia--()--Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing treatments for urologic diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the Jefferies 2014 Global Healthcare Conference. The presentation is scheduled for Monday, June 2, 2014 at 4:30 p.m. EDT in New York City.

The presentation will be webcast live and can be accessed through the Company’s Investor Relations page at www.sophiris.com. A replay of the presentation will be available approximately one hour after the conclusion of the live presentation and available on the Company’s website for 90 days.

About Sophiris

Sophiris Bio Inc. is a biopharmaceutical company developing treatments for urologic diseases. PRX302 is a targeted treatment in Phase 3 development for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate. PRX302 is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing BPH treatments. For more information, please visit www.sophiris.com.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris’ current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, clinical trial enrollment and results, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Company Contact:
Sophiris Bio Inc.
Peter Slover
Chief Financial Officer
(858) 777-1760
or
Corporate Communications and Investor Relations:
Equicom Group
Michael Moore
Investor Relations
858-886-7813
mmoore@tmxequicom.com
or
Canale Communications, Inc.
Jason I. Spark
Corporate Communications and IR
619-849-6005
jason@canalecomm.com

Release Summary

Sophiris Bio, a company developing treatments for urologic diseases, today announced that Randall E. Woods, president and chief executive officer, will present at the Jefferies Healthcare Conference.

Contacts

Company Contact:
Sophiris Bio Inc.
Peter Slover
Chief Financial Officer
(858) 777-1760
or
Corporate Communications and Investor Relations:
Equicom Group
Michael Moore
Investor Relations
858-886-7813
mmoore@tmxequicom.com
or
Canale Communications, Inc.
Jason I. Spark
Corporate Communications and IR
619-849-6005
jason@canalecomm.com